Triacylglycerol mobilization is a central feature in the metabolism of both brown and white adipose tissues. It is generally accepted that the rate-limiting enzyme, the hormone-sensitive lipase, is activated by cyclic-AMP-stimulated protein phosphorylation [ 11. Hence the regulation by hormones of cyclic AMP synthesis and disposal is important in this system. White adipocytes possess B-adrenoceptors together with receptors for corticotropin and glucagon through which G,-coupled activation of adenylate cyclase (EC 4.6.1.1) may be exerted. Conversely, paracrine agents, such as adenosine and E-series prostaglandins, inhibit adenylate cyclase and lipolysis by acting at receptors coupling through Gi. The anti-lipolytic effect of insulin is well documented, although the mechanism of this remains unclear. Clearly, it is pertinent to know the levcls of these agents when attempting to interpret changes in adipose tissue lipolysis in diabetes or in any other physiological state. The plasma insulin, glucagon or corticotropin concentrations are readily obtainable, but localized concentrations of noradrenaline, adenosine or prostaglandins are less readily estimated. In addition, the diabetic state may impose relatively persistent changes upon the processes of lipolytic activation and inhibition, thereby resulting in altered responsiveness to the appropriate agents. It is this aspect which is particularly considered here.
The experimental system
Throughout, male rats aged 6 weeks (160-180 g body wt.) were used. These were made diabetic by a single subcutaneous injection of streptozotocin (100 mg/kg body wt.) and used for experimentation after 2 days. Typically, these animals had plasma glucose concentrations in the range 20-30 mM. Adipocytes were isolated from the epididymal (white) and interscapular (brown) depots by collagenase treatment. These cells were then incubated for study of lipolysis or were used as the starting material for estimation of enzyme activities and receptor binding or measurements of G-protein abundance.
Adenosine is present in fat cell incubations either because it is derived in some manner from the cells and/or because it may be a contaminant of the albumin that should be present in incubations to study lipolysis. Since adenosine is a potent anti-lipolytic agent (see above) and responsiveness to this agonist varies with physiological state (see below), it is essential that unknown quantities of endogenous adenosine be removed if meaningful results are to be obtained. This is achieved by addition of adenosine deaminase (EC 3.5.4.4) (typically 0.5-1 unit/ml). Another reason why this precaution is crucial is because G,-coupled inhibitory agonists appear to impede the effects of different stimulatory agonists in different ways. Whereas adenosine or prostaglandin El (PGE,) simply shift to the right the dose curve for stimulation of Lipolysis by noradrenaline, concentrations of Nh-L-phenylisopropyladenosine (PIA) below 0.1 p~ or of PGE, below 1 p~ can virtually abolish glucagon-stimulated lipolysis at any tested concentration of glucagon [2] . Adenosine deaminase appears to produce a more pronounced effect in incubations of white adipocytes [3] compared with brown cells [4] , sugAbbreviations used: PGE,, prostaglandin E,; PIA, N"-L-phenylisopropyladenosine; EC,,, the concentration of an agonist that causes 50% of its maximum effect.
gesting that the latter operate with lower steady-state levels of adenosine. Actions at adenosine receptors (the A , type) can still be observed experimentally in the presence of adenosine deaminase by using the deaminase-resistant analogue PIA.
Diabetes and white adipose tissue
Enhanced lipolysis in diabetes with the attendant increase in plasma non-esterified fatty acid delivery to the liver assists in the suppression of hepatic fatty acid synthesis and in the enhancement of ketogenesis [S] . The simultaneously increased secretion of very-low-density lipoprotein will contribute to hypertriglyceridaemia and hypercholesterolaemia [6] . Increased fatty acid supply to heart and skeletal muscle results in decreased glucose tolerance [7] .
With regard to activation of lipolysis, streptozotocindiabetes causes a substantial increase in the sensitivity of rat fat cells to glucagon without altering the maximal response to this agent [8] . This effect can be reversed by insulin treatment of the rats. It is important to note that this effect of diabetes on responsiveness to glucagon is only unmasked in the presence of adenosine deaminase [S] . By Streptozotocin-diabetes causes a substantial decrease in the content of G, a-subunit in rat liver plasma membranes 1131. By contrast, hypothyroidism which enhances responsiveness of adipocyte lipolysis to PIA, PGE, and nicotinate increases the fat cell plasma membrane content of G, asubunit [2, 14, 151. It was therefore surprising to find no appreciable difference in the abundance of G, a-subunit in adipocyte plasma membranes from diabetic rats (G. Milligan & D. Saggerson, unpublished work). This does not preclude an alteration in the function of existing G-protein. In summary, diabetes results in some reasonably persistent alterations in the regulation of white fat cell lipolysis. Stimulation by glucagon is enhanced, whereas inhibition by all G,-coupled agonists is diminished by, as yet, unknown mechanisms.
Adopting a more holistic approach, the actual observed release of non-esterified fatty acids by white adipose tissue is not simply a function of the activation state of the hormonesensitive lipase. Rather, it will be representd by the lipase activity minus the proportion of mobilized fatty acid that is recycled back into triacylglycerol by the adipocyte's very active esterification system. As reviewed in [ 16, 171, insulin facilitates adipocyte triacylglycerol synthesis in part by VOl. 17 BIOCHEMICAL SOCIETY TRANSACTIONS stimulating the transport of glucose, the precursor of intracellular glycerolphosphate. Furthermore, insulin plays a more direct acute role in that it prevents/reverses effects of lipolytic hormones to decrease activities of enzymes in the triacylglycerol synthesis pathway [16] [17] [18] [19] [20] . Obviously, thcsc short-term effects of the hormone will be diminished in insulin-dependent diabetes. Longer-term decreases in diabetes also occur in the activities of most of the enzymes of the triacylglycerol synthesis pathway in white adipose tissue [2 1-23] and insulin administration can reverse these changes. In summary, diabetes also decreases the capability of the esterification pathway to re-esterify mobilized fatty acids.
It is to be expected that increased blood flow through adipose tissue should accompany increased lipid mobilization, otherwise deleterious accumulations of fatty acids might occur in the extracellular spaces. It has been shown [24] that a single insulin injection to diabetic rats decreased relative blood flow through epididymal adipose tissue by approx. 60%. This effect was seen 1 h after insulin administration while the animals werc still hyperglycaemic. Infusion of insulin has also been shown by Madsen & Malchow-Moller [ 251 to decrease adipose tissue blood flow, and they proposed that this was mediated by a decreasc in the release of the vasodilator adenosine from adipocytes. The reaction catalysed by the 5'-nucleotidasc (EC 3.1.3.5) ectocnzyme is a possible source of extracellular adenosine. This activity in whitc adipocytes is doubled in diabetes [26] and insulin administration over 2 days reverses this change. It is not known at present how rapidly insulin can exert such an effect. It is noteworthy that 5'-nucleotidase ectoenzyme in some tissues is attached through a glycosyl-phosphatidylinositol anchor [27] and it has been proposed [27] that insulin might promote the release of phosphatidylinositol-anchored proteins from the cell surfacc through the action of a specific phospholipase C. Whether this applies to 5'-nucleotidase remains to bc established. If it is so insulin might indirectly modify adipose tissue blood flow by decreasing the extracellular production of adcnosinc. Conversely, increased formation o f this paracrine agent could be expected in diabetes. The concomitant decrease in responsiveness to the anti-lipolytic action of adenosine (see above) is a necessary adjunct to increased effects upon the vasculature.
Diabetes atid browti udipose tissue
In brown adipose tissue, lipolysis is an important component of the process of thermogenesis, at least during the initial phase of a period of exposure to cold. Fatty acids mobilized in response to noradrenaline release by sympathetic nerves are involved in the activation of the mitochondrial uncoupling protein and also provide the majority of the substrate for respiration (for reviews, see [28, 291) . Brown adipose tissue thermogenesis is impaired in insulindependent diabetes in that basal and noradrenaline-stimulated heat production by rat interscapular brown fat is decreased in streptozotocin-diabetic rats [30] and diabetic rats do not exhibit an increase in metabolic rate after consuming a cafeteria diet [3 11 . It is likely that sympathetic nerve activity in brown adipose tissue is decreased in diabetes (321 together with a decrease in blood flow [24] . However, surprisingly, this is not matched by any decreased capability for lipolysis in brown adipocytes from diabetic rats. In the presence of adenosine deaminase, basal lipolysis was increased and the EC5,, for noradrenaline was significantly decreased but with no change in the maximal rate of lipolysis 1241. In addition, diabetes did not appreciably alter the antilipolytic effect of PIA [24] . By contrast, in the same cells maximum rates of noradrenaline-stimulated 0, uptake were decreased by 58% [24] . It therefore appears that lesions in thermogenesis in diabetes must occur subsequent to stimulation of lipolysis. These lesions are found at multiple loci within brown fat mitochondria and encompass decreased abundance of the uncoupling protein (as measured by [ Triacylglycerol synthesized in the liver from dietary carbohydrate is secreted into the plasma and delivered to peripheral tissues as very-low-density lipoprotein (VLDL). Fatty acids are then derived from the VLDL triacylglycerol by the action of lipoprotein lipase (EC 3.1.1.34) in these peripheral tissues, particularly muscle and adipose tissue sites. In muscle, the fatty acids may be utilized as a source of energy, whereas in adipose tissue they are re-esterified and stored as triacylglycerol. Insulin plays a key role in the co-ordination of these events, the efficiency of which breaks down under conditions of insulin deficiency or insulin resistance. Some consequences of this breakdown include abnormalities of lipoprotein metabolism which are responsible for the hyperlipidaemia characteristic of the diabetic states. This paper has two objectives. First, to review what is known of the role of insulin in controlling VLDL secretion from the liver. Secondly, to discuss how recent findings in this area could account, in part, for the abnormalities of VLDL metabolism observed in the insulin-dependent (IDDM) and non-insulindependent (NIDDM) forms of diabetes. Because these diabetic states differ from each other in their effects on lipoprotein metabolism, each will be dealt with separately bclow.
Hepatic VLDL secretion in NIDDM
This form of diabetes is often referred to as type I1 or maturity-onset diabetes and is characterized partly by tissue resistance to insulin. There is general agreement that this form of diabetes is associated with an increase in the rate of VLDL production (for a review, see [l] ). However, controversy exists as to the exact cause of this defect, particularly in regard to the role of insulin, and studies with experimental animals, in vivo, have often led to difficulty in distinguishing between primary and secondary effects. In view of this, and also because the liver is generally believed to be the major source of the plasma VLDL, at least under normal conditions, many investigations in this area have been carried out using isolated liver preparations in vitro. These studies have shown that many of the metabolic abnormalities associated with NIDDM, when simulated in vitro, produce increases in the rate of hepatic VLDL secretion. For instance, mimicking the hyperglycaemia of NlDDM by increasing the glucose content of the medium gave rise to an increase in the rate of VLDL triacylglycerol secretion from hepatocytes in culture [2, 31. Similarly, elevated concentrations of plasma non-esterified fatty acids are often associated with this diabetic state [4] and it has becn known for some time that treatment of isolated liver preparations with Abbreviations used: VLDL, very-low-density lipoprotcin; IDDM, insulin-dependent diabetes rnellitus; NIDDM, non-insulindependent diabetes rnellitus; apo, apolipoprotein.
Vol. 17 increascd concentrations of non-esterified fatty acids, particularly oleate, also stimulates VLDL triacylglycerol secretion (e.g. [S-lo]). As glucagon rapidly inhibits hepatic VLDL secretion [ I , 11, 121 it is also possible that the hypoglucagonaemia reported to be associated with NlDDM [ 131 may also contribute to the overproduction of hepatic VLDL in this state.
Short-and longer-term effects of insulin on hepatic VLDL secretion
NlDDM is oftcn associated with an absolute increase in the level of plasma insulin, particularly in the postprandial state [ l , 141. The direct effect of insulin, however, on hepat-VLDL secretion is a matter of some controversy. First, it has been proposed that the hyperinsulinaemia which occurs in insulin-resistant states is directly responsible for the enhanced secretion of hepatic VLDL [4, 151 . Several more recent studies, however, have shown that when insulin was added to isolated hepatocytes for periods up to 24 h, the secretion of VLDL triacylglycerol was diminished [3, 12, [16] [17] [18] [19] [20] . There was also a decline in the secretion rate of VLDL-associated phospholipid It might be argued that the inhibitory effect of insulin on hepatic VLDL secretion is merely an artefact of the in vitro model. However, several studies in vivo have also provided evidence that insulin administration results in a decline in hepatic VLDL production [21-231. Although a decreased hepatic fatty acid flux resulting from the anti-lipolytic effect of insulin Cannot be ruled out, it has been shown, in at least one instance, that the inhibitory effect on VLDL secretion was independent of fatty acid uptake by the liver [22] .
Two mechanisms for the inhibitory effect of insulin have been proposed. First, during a 20 h incubation with cultured hepatocytes, insulin, whilst inhibiting the total secretion of apo B and apo E into the medium, also reduced the proportion of these apoproteins which were associated with the VLDL. Concomitantly, the proportion of secreted apoprotein associated withother fractions of the medium such as low-density lipoprotein and albumin increased. It was thus proposed that insulin inhibited hepatic VLDL secretion by interfering with the normal intracellular association of apoprotein and lipid during the assembly of the nascent particles [ 161. Second, insulin inhibited the incorporation of ["S]methionine into both the large-and small-molecularmass variants of apo B [19] . Whether this was a secondary effect of the reduced association of lipid and apoprotein (see above) or whether insulin directly inhibited the synthesis of the apo B variants de novo is not yet known.
The physiological purpose of the inhibitory effect of insulin on hepatic VLDL secretion has been the subject of some debate. During the postprandial period, elevated levels of plasma insulin are coincident with a high rate of hepatic lipid synthesis and an increased entry into the plasma of intestinal
